Back to top
more

Hims & Hers Health (HIMS)

(Real Time Quote from BATS)

$21.66 USD

21.66
6,198,137

+1.16 (5.66%)

Updated Oct 15, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Haemonetics (HAE) Banks on Growing Hospital Arm, New Launches

Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.

What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release?

Quest Diagnostics (DGX) is likely to have maintained its robust base business performance in the second quarter of 2024. However, nosediving COVID-19 testing revenues may limit growth.

Is It Wise to Retain Henry Schein (HSIC) in Your Portfolio Now?

Robust acquisitions and a widespread distribution network bode well for Henry Schein's (HSIC) operations.

Thermo Fisher (TMO) Inks New Partnership for myeloMATCH Trial

Thermo Fisher (TMO) announces a partnership with the National Cancer Institute for the myeloMATCH precision medicine umbrella trial to fuel research regarding new treatments for AML and MDS.

Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Ideas feature highlights: Hims & Hers Health and Ero Copper

Hims & Hers Health and Ero Copper are part of the Zacks Investment Ideas article.

Derek Lewis headshot

3 Companies Set to Positively Surprise this Earnings Season

Earnings season has arrived, and these three companies look set to positively surprise. How will shares react?

Benjamin Rains headshot

2 Top-Ranked Cheap Growth Stocks to Buy in July and Hold

The two stocks trading under $25 per share we dive into today boast impressive growth outlooks and their improving earnings estimates help them land Zacks Rank #1 (Strong Buys).

Here's How Abbott (ABT) is Placed Ahead of Q2 Earnings Release

Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.

Hyperfine (HYPR) Inks New Partnerships to Expand in Europe

Hyperfine (HYPR) announces that it has signed agreements with experienced and accomplished distributors in Germany, Austria, Switzerland, and key Nordic markets for its Swoop, a portable MRI system.

STERIS (STE) AST Business Expands, New Offerings Aid Growth

STERIS' (STE) AST successfully offers an extensive range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.

Illumina (ILMN) Buys Fluent, Grows in Single Cell Research

By integrating Fluent's unique technology with Illumina's (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a comprehensive solution for single-cell multiomic analysis.

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.

Thermo Fisher (TMO) to Open New NanoPort Facility in Taiwan

Thermo Fisher (TMO) announces the opening of NanoPort, the company???s first electron microscopy demo center in Taiwan, strategically located in the region???s semiconductor manufacturing hub.

Thermo Fisher (TMO) Strategic Buyouts Aid Amid Macro Issues

Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.

Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.

QIAGEN (QGEN) Expands in NGS and FIGG With New Partnership

QIAGEN (QGEN) announces a collaboration with the Snow Molecular Anthropology Lab at the University of Montana to enhance the identification of human remains of Indigenous people and African Americans.

Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy

Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.

Here's Why Holding Align Technology (ALGN) Stock Could Pay Off

Align Technology's (ALGN) Invisalign portfolio expansion efforts spark optimism.

Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine

Valneva (VALN) gets European Commission???s marketing authorization in Europe for Valneva???s single-dose Chikungunya vaccine, IXCHIQ. The company is set to launch IXCHIQ in Europe in late 2024.

Are Medical Stocks Lagging Hims & Hers Health (HIMS) This Year?

Here is how Hims & Hers Health, Inc. (HIMS) and Novo Nordisk (NVO) have performed compared to their sector so far this year.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Carvana, Adobe, Amgen in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Should You Hold STERIS (STE) Stock Now? Here's What to Consider

STERIS' (STE) Healthcare business and strong rebound prospects of the AST segment appear encouraging. However, macroeconomic concerns remain a challenge.

Debanjana Dey headshot

Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?

Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Henry Schein (HSIC) Banks on Strategic Buyouts Amid Macro Issues

Henry Schein's (HSIC) revenue growth is supported by niche acquisitions and partnerships.